Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin mesylate + trastuzumab biosimilar SB3
- Development stage
- Unknown
- Lead developer
- Samsung Bioepis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Eribulin mesylate + trastuzumab biosimilar SB3 is a combination therapy being investigated for the treatment of HER2-positive recurrent or metastatic breast cancer. The regimen consists of eribulin mesylate (Halaven), a synthetic analogue of halichondrin B that acts as a non-taxane microtubule dynamics inhibitor, and SB3 (Samfenet/Ontruzant), a biosimilar of the monoclonal antibody trastuzumab. Eribulin inhibits the growth phase of microtubules without affecting the shortening phase, sequestering tubulin into non-productive aggregates and inducing G2/M cell cycle arrest. SB3 targets the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2), blocking downstream proliferative signaling and inducing antibody-dependent cellular cytotoxicity (ADCC). This combination is specifically being evaluated in the Phase II ESPERO trial as a salvage therapy for patients who have previously failed standard HER2-directed treatments, including trastuzumab and ado-trastuzumab emtansine (T-DM1).
- Brand names
- HalavenSamfenetOntruzant
- Other names
- eribulin mesylate + Samfenet-Seoul National University Hospital-breast cancer (HER2-positive)eribulin mesylate + SB3eribulin + Samfeneteribulin + Ontruzant
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on eribulin mesylate + trastuzumab biosimilar SB3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin mesylate + trastuzumab biosimilar SB3.